-
Professor Xiaoyu Zhu: Double-Negative T Cells — A New Breakthrough in Acute Myeloid Leukemia Therapy | 9th CSCO Hematologic Oncology Congress
In the height of summer, Harbin—known as the “Ice City”—welcomed a gathering of scientific minds. From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The congress brought together top experts from China and abroad to discuss advancements in leukemia, lymphoma,…
-
2025 ICML | MD Anderson’s Experience: Can Radiation Be a “New Drug”? How Low-Dose, Large-Field Radiation Is Shaping the CAR-T Bridging Strategy
At this year’s meeting, Professor Bouthaina S. Dabaja from MD Anderson Cancer Center delivered a special presentation titled “MD Anderson Updates—New Frontiers in Hematologic Radiation Oncology: Enhancing the Effects of…
-
Professor Minghui Duan: The Central Role of Genetic Testing in Hematologic Malignancies and Its Guidance for Personalized Therapy
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin. The event brought together top experts from China and abroad to discuss key issues in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics spanned basic research, innovative drug development, precision…
-
Professor Yu Zhang: Optimizing the Diagnostic and Treatment Pathway for AML – The Southern Hospital Experience | 9th CSCO Hematologic Oncology Congres
From July 11 to 13, 2025, the 9th Annual Hematologic Oncology Congress hosted by the Chinese Society of Clinical Oncology (CSCO) took place in Harbin. The conference brought together leading experts from China and abroad to discuss key topics in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Topics ranged from basic research and innovative…
-
Prof. Masatoshi Kudo on Comparing IO Regimens in HCC
At ESMO, Professor Masatoshi Kudo from Kindai University shared results from a matching-adjusted indirect comparison of nivolumab + ipilimumab (CheckMate 9DW) versus durvalumab + tremelimumab (HIMALAYA) and atezolizumab + bevacizumab…
-
Prof. Markus Moehler on RATIONAL 305 and Global Progress in Gastric Cancer
At ESMO, Professor Markus Moehler, Head of the GI Oncology Unit at the University Medical Center Mainz, shared findings from the phase III RATIONAL 305 trial, which evaluated tislelizumab plus…
-
China-Germany-Japan Roundtable | Insights on the TALENT Study in HCC
At a recent international roundtable, experts from China, Germany, and Japan shared their perspectives on the TALENT study, which evaluated the combination of TACE with atezolizumab and bevacizumab for patients…
-
ESMO GI | A China-Europe Dialogue with Professor Gang Jin & Professor Teresa Macarulla on PANOVA-3: Tumor-Treating Fields Help Patients with Locally Advanced Pancreatic Cancer Live Longer—and Better
Oncology Frontier invited Professor Gang Jin, principal investigator of PANOVA-3 in China and Chair of the Department of Hepatobiliary and Pancreatic Surgery at Changhai Hospital, Naval Medical University, and Professor…
Connecting Medical Expertise through Media